Simcere Pharmaceutical Group (HKG: 2096) reported 2025 financial results, with revenue rising 16.5% YoY to RMB 7.7 billion (USD 1.1 billion). Innovative drug business surged 27.9% to RMB 6.304 billion (USD 913 million), driving profits attributable to shareholders up 86.2% to RMB 1.344 billion (USD 194 million). The company launched two new innovative products – Quviviq (daridorexan) for insomnia and Enzeshu (suvemcitug) for platinum-resistant ovarian cancer – expanding its neuroscience and oncology franchises.
Financial Highlights
Metric
2025 Result
YoY Change
Strategic Driver
Total Revenue
RMB 7.7B (USD 1.1B)
+16.5%
Innovative drug momentum + new product launches
Innovative Drug Revenue
RMB 6.304B (USD 913M)
+27.9%
81.9% of total revenue – transformation complete
Profit Attributable
RMB 1.344B (USD 194M)
+86.2%
Operating leverage + high-margin innovation mix
Neuroscience
RMB 2.753B (USD 398M)
+26.6%
Core franchise strength
Autoimmune
RMB 1.892B (USD 274M)
+4.5%
Stable contribution
Oncology
RMB 1.987B (USD 287M)
+53.0%
Fastest-growing segment – Enzeshu launch impact
Other
RMB 1.099B (USD 159M)
-18.7%
Portfolio rationalization
2025 New Product Launches
Product
Indication
Differentiation
Launch Impact
Quviviq (daridorexan)
Adult insomnia (sleep onset/maintenance)
Non-controlled substance (Schedule IV exempt) – addresses abuse liability concerns vs. zolpidem
Neuroscience expansion – RMB 500M+ peak potential
Enzeshu (suvemcitug)
Platinum-resistant ovarian/fallopian tube/peritoneal cancer
Combination with paclitaxel, doxorubicin liposomes, or topotecan; ≤1 prior systemic therapy positioning
Oncology 53% growth driver; addresses high unmet need in recurrent disease
Stable cash flow – established RA/lupus positioning
Other
RMB 1.099B
-18.7%
Legacy products
Portfolio optimization – divestment of non-core assets
Forward‑Looking Statements This brief contains forward‑looking statements regarding 2026 revenue growth, Quviviq/Enzeshu market penetration, and therapeutic area expansion. Actual results may differ due to competitive dynamics in insomnia (lemborexant, daridorexan) and ovarian cancer (PARP inhibitors, bevacizumab), and NRDL negotiation outcomes for new products.-Fineline Info & Tech
By Fineline Cube 